ArticleFrontiers in oncology2021

CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer.

Yuan-Ke Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.